Lisata Therapeutics Inc (LSTA)

[Viperciara]

Dr. Adel Nada leads the development of NBS-03, NeoStem’s proprietary autologous expanded regulatory T-cell platform, in autoimmunity and allergy indications, including type 1 diabetes. Before coming to NeoStem, Dr. Nada led the clinical development of Baxter’s autologous CD34+ cell therapy for a variety of cardiovascular indications, and was responsible for the Phase 3 program in chronic myocardial ischemia. Before then, Dr. Nada led the Clinical Pharmacology Medical Department at Abbott Laboratories, which provided strategic and technical guidance to Abbott’s early clinical development pipeline across all therapeutic areas, and was responsible for the cardiac safety and clinical pharmacogenetics organizations.
In addition, Dr. Nada was the medical director for Abbott’s immunology project team developing a novel investigational agent for rheumatoid arthritis.


http://www.endocrineweb.com/author/13137/nada